As a result, various clinical trials with non-selective cytokine inhibition by glucocorticoids (dexamethasone) and selective targeted cytokine inhibition (blocking IL-1, IL-6, GM-CSF, etc.)are being pursued for managing COVID-19(https://www.covid-trials.org). This evidence concerns the gene IL1A and COVID-19.